Menu
Recruiting NCT07413848

qNOX Response to Nociceptive Motor Events During Procedural Sedation

Observational Monitoring Noxious Events Using EEG-Derived Pain Indices Procedural Sedation and Analgesia Monitored Anesthesia Care

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Monitoring Noxious Events Using EEG-Derived Pain Indices, Procedural Sedation and Analgesia, Monitored Anesthesia Care. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Performance of the CONOX Monitor Without Neuromuscular Blockade: qCON and qNOX Responses to Nociceptive Motor Events During Procedural Sedation

Overview

The goal of this observational study is to evaluate whether the CONOX monitor can detect pain during sedation in patients undergoing urological procedures. The main questions it aims to answer are: Does the qNOX index respond to pain-related motor responses during urological procedural sedation? Does the qNOX index show greater responsiveness to painful episodes compared to blood pressure and heart rate? Participants undergoing urological procedures (such as cystoscopy) under sedation as part of their regular medical care will have continuous brain activity monitoring with the CONOX device. All monitoring displays (CONOX monitor, vital signs monitor, and target-controlled infusion pump) will be video-recorded throughout the procedure to capture synchronized data including qCON, qNOX, EMG, heart rate, blood pressure, oxygen saturation, and drug concentrations. Researchers will analyze the relationship between these indices and spontaneous movements triggered by painful stimulation to evaluate the monitor's performance compared to traditional vital signs.

Detailed description

STUDY RATIONALE

Adequate monitoring of sedation depth and nociception is essential during monitored anesthesia care (MAC). While processed EEG monitors assess hypnotic depth, monitoring pain remains challenging. The CONOX monitor uniquely provides two indices: qCON for sedation depth and qNOX for nociception probability.

Most CONOX studies have used neuromuscular blockade, which prevents motor responses and limits validation of the qNOX index against observable pain reactions. Furthermore, data during procedural sedation and MAC is limited. The absence of neuromuscular blockade during MAC allows studying the relationship between qNOX values and actual pain-triggered motor responses, providing a concrete reference for nociception assessment.

This study evaluates whether an EEG-based nociception index can reliably detect pain when motor responses are not suppressed. If the qNOX index demonstrates adequate performance, it could provide clinicians with a tool for optimizing analgesic administration while minimizing opioid consumption.

STUDY DESIGN

This is a prospective, observational, single-arm cohort study evaluating CONOX monitor performance during procedural sedation without neuromuscular blockade at Ankara University Faculty of Medicine. The study involves no interventions beyond standard clinical care.

The study will enroll 120 adult patients (≥18 years) undergoing elective urological procedures (cystoscopy, ureteroscopy, transurethral resection) under MAC. These procedures involve intermittent painful stimulation and typically do not require neuromuscular blockade. Patient recruitment and data collection will occur over 4 months, followed by 2 months for analysis.

Processed EEG monitoring is part of standard practice in our department. The CONOX monitor will be used for all enrolled patients. The only study-specific procedure is video recording of monitoring displays (not patients) for subsequent analysis.

METHODS

Anesthesia Protocol:

Patients receive standard ASA monitoring. Anesthesia consists of intravenous fentanyl (1 mcg/kg) followed by propofol target-controlled infusion (TCI) using the Eleveld model. Initial target effect-site concentration is 1.5 mcg/mL, titrated to achieve adequate sedation depth (MOAAS ≤1). Patients maintain spontaneous ventilation with airway support as needed. No neuromuscular blockade is used.

Monitoring and Data Collection:

The CONOX monitor continuously records qCON (hypnotic depth), qNOX (nociception), EMG (electromyographic activity), and burst suppression ratio. Standard monitors record ECG, blood pressure, heart rate, SpO₂, and capnography. The TCI pump displays real-time propofol effect-site concentration.

All monitoring displays are video-recorded throughout procedures to capture synchronized data for post-hoc analysis. Researchers provide verbal timestamps to mark clinical events (drug administration, procedure start, motor responses). Videos capture only monitor screens, not patient images.

Primary Endpoint:

The primary endpoint is change in qNOX index from baseline to peak during spontaneous motor responses triggered by surgical stimulation. Motor responses include extremity/trunk movements, facial grimacing, or vocalization, identified by real-time clinical observation.

Data Analysis:

Video recordings are systematically reviewed to extract monitoring values at baseline and during clinical events. For motor response events, peak values and time-to-peak are recorded for each parameter.

STATISTICAL ANALYSIS

Power analysis determined 30 motor response events are required for paired t-test comparing baseline versus peak qNOX (alpha=0.05, power=0.95). Based on estimated 25% incidence and accounting for potential data loss, 120 patients will be enrolled.

Primary analysis uses paired t-test (or Wilcoxon test if non-normal) to compare qNOX at baseline versus during motor responses. ROC curve analysis evaluates discriminative ability of qNOX, heart rate, and blood pressure for predicting motor responses. Secondary analyses include correlation analyses and repeated measures analysis for induction/emergence dynamics. Statistical significance: p\<0.05 (two-tailed).

ETHICS AND SAFETY

This observational study involves no interventions beyond standard care. All management decisions follow routine clinical practice. The study has ethics approval from Ankara University Faculty of Medicine Clinical Research Ethics Committee. Written informed consent is obtained from all participants. The study follows Declaration of Helsinki and Good Clinical Practice guidelines.

Primary outcome measures

  • Change from Baseline in Quantium Nociception Index (qNOX) During Motor Responses to Noxious Stimulation [Time frame: During the procedure (approximately 15-60 minutes per patient)]
Secondary outcome measures (4)
  • Comparison of qNOX Responsiveness Versus Hemodynamic Parameters During Motor Responses [Time frame: During motor response events (if occurred) throughout the surgical procedure]
  • Correlation Between EMG Activity and qCON/qNOX Indices [Time frame: Throughout the surgical procedure (approximately 15-60 minutes)]
  • Index Dynamics During Induction and Emergence from Sedation [Time frame: Induction: 0-10 minutes; Emergence: from TCI stop until recovery of consciousness]
  • Incidence of Pain-Related Motor Responses During Procedural Sedation [Time frame: During the surgical procedure (approximately 15-60 minutes)]

Eligibility criteria

Inclusion criteria

  • Age 18 years or older
  • Scheduled for elective diagnostic or therapeutic urological procedures (cystoscopy, ureteroscopy, prostate biopsy, intradetrusor botulinum toxin injection) under monitored anesthesia care
  • Able to provide written informed consent

Exclusion criteria

  • Known central neurological disease (epilepsy, Alzheimer's disease, Parkinson's disease, stroke) or history of brain surgery
  • Body Mass Index (BMI) ≥35 kg/m²
  • Known allergy to anesthetic agents used in the study (propofol, fentanyl, lidocaine)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Turkey (Türkiye) · 1 center
  • Ankara University — Ankara

Publications

  • Schuller PJ, Pretorius JPG, Newbery KB. Response of the Conox quantitative electroencephalographic monitor to neuromuscular block in awake volunteers. Br J Anaesth. 2025 Sep;135(3):660-667. doi: 10.1016/j.bja.2025.05.023. Epub 2025 Jul 18. PMID 40683805
  • Jensen EW, Valencia JF, Lopez A, Anglada T, Agusti M, Ramos Y, Serra R, Jospin M, Pineda P, Gambus P. Monitoring hypnotic effect and nociception with two EEG-derived indices, qCON and qNOX, during general anaesthesia. Acta Anaesthesiol Scand. 2014 Sep;58(8):933-41. doi: 10.1111/aas.12359. Epub 2014 Jul 4. PMID 24995461
  • Linassi F, Vide S, Ferreira A, Schneider G, Gambus P, Kreuzer M. Relationships between the qNOX, qCON, burst suppression ratio, and muscle activity index of the CONOX monitor during total intravenous anesthesia: a pilot study. J Clin Monit Comput. 2024 Dec;38(6):1281-1290. doi: 10.1007/s10877-024-01214-6. Epub 2024 Sep 12. PMID 39266928

Identifiers

NCT: NCT07413848 · 2025/433

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗